Meridian Bioscience (VIVO) Misses Q1 EPS by 5c; Lowers Outlook, Cuts Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward
January 25, 2017 7:30 AM ESTGENERAL HIGHLIGHTS
CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year; reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases... More